Zou
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
Asia development bank chief on financing green transition
Zou Jiayi is president and chairwoman of the board of directors of the Asian Infrastructure Investment Bank (AIIB), a multilateral development lender headquartered in Beijing and inaugurated in 2016. Before leading AIIB, Zou was deputy secretary general of the national committee of the Chinese People’s Political Consultative Conference, China’s top political advisory body. She previously held senior roles at the Ministry of Finance, including as vice-minister, and as part of her three...
Doctors thought this kidney drug helped some patients. It may help millions more.
Doctors thought this kidney drug helped some patients. It may help millions more. - Date: - June 8, 2026
This strange new phase of matter could transform quantum technology
This strange new phase of matter could transform quantum technology - Date: - May 30, 2026 - Source: - Brown University - Summary: - By stacking custom-designed silver nanoparticles like nanoscale LEGO bricks, scientists stabilized a mysterious crystal phase that had never been observed before. The material not only solves a longstanding puzzle in materials science but also exhibits promising quantum properties at room temperature.
In situ nanocrystal confinement for efficient blue perovskite LEDs
Abstract Metal halide perovskites have emerged as promising semiconductors for light-emitting diodes (LEDs) owing to their excellent luminescence properties1. However, their performance remains limited, primarily owing to the inherent contradiction between ‘high crystallinity’ and ‘small size’ in the in situ synthesis of perovskite nanocrystals on substrates. Here we report efficient blue perovskite LEDs (PeLEDs) achieved via in situ polymerization-driven nanocrystal confinement to...
Molecular glue degraders of HuR suppress BRAF-mutant colorectal cancer
Abstract BRAF gain-of-function mutations, particularly BRAF(V600E), affect roughly 10% of all patients with colorectal cancer (CRC), and portend poor prognosis with limited therapeutic interventions. BRAF inhibitors such as encorafenib are ineffective due to MAPK pathway reactivation driven by BRAF dimerization. Combined inhibition of BRAF and EGFR, although approved therapies, results in short survival benefits and frequent treatment resistance and relapse1,2,3.